Offer - Urjas Oil for just ₹ 1 X
Imitop is a commercial drug that is prescribed in the form of Injection. Other than this, Imitop has some other therapeutic uses, which have been discussed ahead.
The optimal dosage of Imitop is largely dependent on the individual's body weight, medical history, gender and age. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
Some other side effects of Imitop have been listed ahead. Normally, these side effects of Imitop are not long lasting and go away when the treatment is finished. If, however, they worsen or do not go away, please speak with your physician.
It is also important to note that Imitop has a Moderate effect for pregnant women and Moderate effect on lactating mothers. It is important to know if Imitop has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Imitop related warnings section.
Imitop is not recommended if you suffer from certain medical conditions as it can have adverse effects. Kidney Disease, Kidney Disease are examples of such conditions. Other contraindications of Imitop have been discussed in the sections ahead.
Besides this, Imitop may also have severe interaction with some medicines. Refer to the list below for further details.
In addition to these precautions, you may also note that Imitop is safe while driving, and is is addictive in nature.
Imitop is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Adult |
|
Geriatric |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
Is the use of Imitop safe for pregnant women?
Imitop can have harmful effects in pregnant women. If you experience any discomfort after using Imitop, then discontinue the use and take your doctor's advice.
Is the use of Imitop safe during breastfeeding?
Imitop may lead to some side effects in breastfeeding women. If you witness any unusal symptoms after taking Imitop, discontinue its use and call your doctor right away. Follow your doctor's advice regarding the use of Imitop.
What is the effect of Imitop on the Kidneys?
There may be some adverse effects on kidney after taking Imitop. If you observe any such side effects, stop taking this drug. Consume this medicine again only if your doctor advises you to do so.
What is the effect of Imitop on the Liver?
You may experience side effects on your liver after taking Imitop. If this happens, then discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Imitop on the Heart?
Side effects of Imitop rarely affect the heart.
Imitop should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Imitop unless your doctor advises you to do so -
Is this Imitop habit forming or addictive?
Imitop is not addictive in nature.
Interaction between Food and Imitop
Taking Imitop with some specific foods may delay its effect. Talk to your doctor about this.
Interaction between Alcohol and Imitop
Consuming Imitop with alcohol can have many serious effects on your body.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Primaxin® (imipenem and cilastatin)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 731
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 676-678